Vasopressor Agents in Pulmonary Hypertension Crisis

Comparison of the Efficacy and Safety of Dopamine, Norepinephrine and Epinephrine in the Treatment of Pulmonary Hypertensive Crisis Under Hemodynamic Monitoring

Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring

Inclusion Criteria:

1. Age > 18 years old;
2. Signed informed consent form;
3. Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH);
4. Presenting with manifestations of pulmonary hypertensive crisis;
5. Receiving both diagnosis and treatment in-hospital;
6. No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment.

Exclusion Criteria:

1. At SCAI stage D or stage E ;
2. Patients who only receive a diagnosis but no treatment in the hospital;
3. Uncontrolled hyperthyroidism;
4. Complicated with angle-closure glaucoma;
5. Hypersensitivity to the study drug;
6. Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane;
7. Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide);
8. Pregnancy;
9. Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.